Literature DB >> 22752360

Cardiac side effects of anticancer treatments: new mechanistic insights.

Carrie Geisberg1, Laura Pentassuglia, Douglas B Sawyer.   

Abstract

Damage to heart cells leading to heart failure is a known complication of well-established cancer therapies including anthracycline antibiotics and radiation therapy, and the cardiovascular complications of these therapies has been controlled in large part through dose limitations and modifications of delivery methods. Recent research into the cellular and molecular mechanisms for the cardiovascular effects of these therapies may lead to other cardioprotective strategies that improve effectiveness of cancer treatments. Newer cancer therapies that have been developed based upon specifically targeting oncogene signaling also have been associated with heart failure. Rapid development of a detailed understanding of how these agents cause cardiac dysfunction promises to improve outcomes in cancer patients, as well as stimulate concepts of cardiovascular homeostasis that will likely accelerate development of cardiovascular therapies.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22752360      PMCID： PMC3693763          DOI： 10.1007/s11897-012-0098-4

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN： 1546-9530


  92 in total

1.  Adult cardiac stem cells are multipotent and support myocardial regeneration.

Authors:  Antonio P Beltrami; Laura Barlucchi; Daniele Torella; Mathue Baker; Federica Limana; Stefano Chimenti; Hideko Kasahara; Marcello Rota; Ezio Musso; Konrad Urbanek; Annarosa Leri; Jan Kajstura; Bernardo Nadal-Ginard; Piero Anversa
Journal:  Cell       Date:  2003-09-19       Impact factor: 41.582

2.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

3.  ErbB2 is essential in the prevention of dilated cardiomyopathy.

Authors:  Steven A Crone; You-Yang Zhao; Lian Fan; Yusu Gu; Susumu Minamisawa; Yang Liu; Kirk L Peterson; Ju Chen; Ronald Kahn; Gianluigi Condorelli; John Ross; Kenneth R Chien; Kuo-Fee Lee
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

Review 4.  Untangling the ErbB signalling network.

Authors:  Y Yarden; M X Sliwkowski
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

5.  Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity.

Authors:  Douglas B Sawyer; Christian Zuppinger; Thomas A Miller; Hans M Eppenberger; Thomas M Suter
Journal:  Circulation       Date:  2002-04-02       Impact factor: 29.690

6.  Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt.

Authors:  Ryuji Fukazawa; Thomas A Miller; Yukio Kuramochi; Stefan Frantz; Young Dae Kim; Mark A Marchionni; Ralph A Kelly; Douglas B Sawyer
Journal:  J Mol Cell Cardiol       Date:  2003-12       Impact factor: 5.000

7.  Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes.

Authors:  Chee Chew Lim; Christian Zuppinger; Xinxin Guo; Gabriela M Kuster; Michiel Helmes; Hans M Eppenberger; Thomas M Suter; Ronglih Liao; Douglas B Sawyer
Journal:  J Biol Chem       Date:  2003-12-14       Impact factor: 5.157

8.  Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy.

Authors:  Cemil Ozcelik; Bettina Erdmann; Bernhard Pilz; Nina Wettschureck; Stefan Britsch; Norbert Hübner; Kenneth R Chien; Carmen Birchmeier; Alistair N Garratt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-18       Impact factor: 11.205

Review 9.  CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer.

Authors:  Lee F Allen; Irene A Eiseman; David W Fry; Peter F Lenehan
Journal:  Semin Oncol       Date:  2003-10       Impact factor: 4.929

10.  Titin determines the Frank-Starling relation in early diastole.

Authors:  Michiel Helmes; Chee Chew Lim; Ronglih Liao; Ajit Bharti; Lei Cui; Douglas B Sawyer
Journal:  J Gen Physiol       Date:  2003-02       Impact factor: 4.086
View more
  8 in total

Review 1.  Cancer chemotherapy and cardiac arrhythmias: a review.

Authors:  Juan Tamargo; Ricardo Caballero; Eva Delpón
Journal:  Drug Saf       Date:  2015-02       Impact factor: 5.606

2.  Risk of cardiovascular adverse events from trastuzumab (Herceptin(®)) in elderly persons with breast cancer: a population-based study.

Authors:  H-T Tsai; C Isaacs; A Z Fu; J L Warren; A N Freedman; A Barac; C-Y Huang; A L Potosky
Journal:  Breast Cancer Res Treat       Date:  2014-01-28       Impact factor: 4.872

3.  Managing cardiotoxicity of chemotherapy.

Authors:  Alessandro Colombo; Carlo A Meroni; Carlo M Cipolla; Daniela Cardinale
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-08

Review 4.  Neuregulin as a heart failure therapy and mediator of reverse remodeling.

Authors:  Cristi L Galindo; Sergey Ryzhov; Douglas B Sawyer
Journal:  Curr Heart Fail Rep       Date:  2014-03

5.  Mechanism-based engineering against anthracycline cardiotoxicity.

Authors:  Thomas Force; Yibin Wang
Journal:  Circulation       Date:  2013-06-11       Impact factor: 29.690

6.  Aspartate facilitates mitochondrial function, growth arrest and survival during doxorubicin exposure.

Authors:  Ken Dornfeld; Michael Madden; Andrew Skildum; Kendall B Wallace
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

7.  Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model.

Authors:  Chhanda Bose; Sanjay Awasthi; Rajendra Sharma; Helen Beneš; Martin Hauer-Jensen; Marjan Boerma; Sharda P Singh
Journal:  PLoS One       Date:  2018-03-08       Impact factor: 3.240

Review 8.  A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.

Authors:  Paolo Spallarossa; Nicola Maurea; Christian Cadeddu; Rosalinda Madonna; Donato Mele; Ines Monte; Giuseppina Novo; Pasquale Pagliaro; Alessia Pepe; Carlo G Tocchetti; Concetta Zito; Giuseppe Mercuro
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2016-05       Impact factor: 2.160
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.